-$0.78 Earnings Per Share Expected for Crispr Therapeutics AG (CRSP) This Quarter
Wall Street analysts forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings per share (EPS) of ($0.78) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.89) and the highest estimate coming in at ($0.57). The business is expected to issue its next earnings results on Thursday, March 14th.
On average, analysts expect that Crispr Therapeutics will report full year earnings of ($3.26) per share for the current fiscal year, with EPS estimates ranging from ($3.33) to ($3.08). For the next financial year, analysts anticipate that the business will post earnings of ($3.47) per share, with EPS estimates ranging from ($4.05) to ($1.86). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.33). The business had revenue of $0.56 million during the quarter, compared to the consensus estimate of $2.64 million. Crispr Therapeutics had a negative return on equity of 40.41% and a negative net margin of 331.84%. The business’s revenue was down 76.6% on a year-over-year basis. During the same period last year, the company earned ($0.62) EPS.
Shares of NASDAQ CRSP traded down $0.42 during mid-day trading on Friday, reaching $35.92. The company’s stock had a trading volume of 616,500 shares, compared to its average volume of 1,172,666. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -20.80 and a beta of 3.79. Crispr Therapeutics has a 52 week low of $17.40 and a 52 week high of $73.90.
Large investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. purchased a new stake in shares of Crispr Therapeutics in the second quarter worth about $116,000. TRUE Private Wealth Advisors purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $122,000. Signaturefd LLC lifted its position in shares of Crispr Therapeutics by 123.8% in the second quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after buying an additional 1,300 shares in the last quarter. SeaCrest Wealth Management LLC lifted its position in shares of Crispr Therapeutics by 202.9% in the second quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after buying an additional 1,826 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Crispr Therapeutics by 66.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock worth $166,000 after buying an additional 1,127 shares in the last quarter. Institutional investors own 43.88% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Featured Article: Exchange-Traded Funds (ETFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.